Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen recept...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Yongbao Wei, Ruochen Zhang, Dewen Zhong, Zhensheng Chen, Gen Chen, Minggen Yang, Le Lin, Tao Li, Liefu Ye, Lili Chen, Qingguo Zhu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2023-10-01
Ráidu:	Frontiers in Pharmacology
Fáttát:	prostate cancer androgen deprivation therapy apalutamide neoadjuvant therapy radical prostatectomy
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1284899/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!